December 2020 in “Forum Dermatologicum” Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.
32 citations
,
December 2019 in “The Journal of clinical investigation/The journal of clinical investigation” A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.
July 2025 in “Journal of Investigative Dermatology” Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
37 citations
,
May 2004 in “Multiple Sclerosis Journal” The article concludes that proper injection techniques and patient education can prevent serious skin reactions from multiple sclerosis medications.
May 2025 in “International Journal of Science and Research (IJSR)” Stopping azathioprine led to full hair regrowth and recovery in 2.5 months.
January 2026 in “International Journal of Innovative Technologies in Social Science” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
2 citations
,
August 2025 in “Scientific Reports” Pexidartinib often causes liver issues and fatigue, especially in women.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
1 citations
,
September 2023 in “Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science)” Avian yolk antibodies offer a promising, ethical alternative for disease prevention and therapy.
February 2023 in “Research Square (Research Square)” Genetic testing confirmed a rare skin disorder in a young girl, which improved with zinc supplementation.
January 2024 in “Wiadomości Lekarskie” Probiotics with Lactobacillus reuteri improve IBS symptoms in children.
10 citations
,
August 2019 in “European Journal of Dermatology” The document did not conclude on apremilast's effectiveness for severe alopecia areata.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
April 2023 in “Journal of Investigative Dermatology” The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
January 2025 in “Veterinary Record Case Reports” The dog's skin condition improved quickly with treatment and did not return.
138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
19 citations
,
April 2023 in “Antibiotics” Azelaic acid in a special gel is more effective against skin fungi than regular azelaic acid.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
2 citations
,
January 2022 in “JAAD Case Reports” The rash resolved after stopping ponatinib.
20 citations
,
March 2019 in “Case Reports in Dermatology” IL-17 inhibitors for psoriasis may cause unexpected hair loss.
October 2018 in “The American journal of gastroenterology” Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
April 2017 in “Journal of Investigative Dermatology” The document concludes that various topical treatments show promise for skin conditions like atopic dermatitis, psoriasis, and hair loss.